|
시장보고서
상품코드
1807689
세계의 통풍 치료제 시장 규모, 점유율, 동향, 업계 분석 : 병상별, 약제 클래스별, 유통 채널별, 지역별 - 시장 예측(2025-2034년)Gout Therapeutics Market Size, Share, Trend, Industry Analysis Report By Disease Condition (Acute Gout, Chronic Gout), By Drug Class, By Distribution Channel, By Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최신 조사에 따르면 통풍 치료제 시장 규모는 2034년까지 61억 5,000만 달러에 달할 전망입니다. 이 조사 리포트는 현재 시장 역학의 상세 인사이트와 향후 시장 성장에 관한 분석을 제공하고 있습니다.
통풍 치료제 시장은 요산 나트륨 결정의 침착으로 인한 고요산혈증과 재발성 염증성 관절염을 관리하기 위한 임상적 요구에 대응하고 있습니다. 치료에는 급성기 관리와 재발 및 관절 손상을 예방하기 위한 장기적인 요산 수치 감소 전략이 모두 포함됩니다. 시장 성장의 배경에는 비만율 증가, 좌식 생활습관, 고혈압, 만성신장질환 등 대사성 질환으로 인한 질병 부담 증가가 있습니다. 진단이 빨라지고 환자와 의료진 모두의 인식이 개선되면서 치료를 조기에 시작할 수 있게 되었고, 치료 개입을 받을 수 있는 환자층이 확대되고 있습니다.
업계는 특히 기존 치료에 반응하지 않는 환자들을 위해 부작용을 최소화하면서 효능을 향상시키는 표적치료제에 투자하고 있습니다. 생물제제의 혁신, 정밀의료에 대한 접근, 합병증을 고려한 제제에 대한 집중 등의 동향이 주목받고 있습니다. 요산 운송 조절제 및 인터류킨-1B 억제제 파이프라인의 확장으로 비즈니스 기회가 창출되고 있습니다. 규제 당국은 획기적인 치료제에 대한 신속한 개발 경로를 제공하고 R&D 투자를 장려하고 있습니다. 양사는 전략적 제휴를 통해 신약 공동 개발 및 상품화, 전문 지식 공유 및 지역 시장 접근성을 활용하고 있습니다. 시장은 또한 치료 순응도 툴와 디지털 헬스 통합을 도입한 환자 중심 치료 모델로 전환하는 것을 목격하고 있습니다.
통풍 치료제 시장 : 분석 개요
약품군별로는 급성 통풍 발작에 수반되는 염증과 통증을 빠르게 억제하는 NSAIDs 부문이 2024년 매출 점유율에서 ∼43%를 차지하며 시장을 주도하고 있습니다.
질환별로는 만성 통풍 분야가 장기 관리 요법에 대한 수요 증가로 인해 2024년 가장 큰 매출 점유율을 차지했습니다.
북미는 강력한 의료 인프라, 조기 진단 및 전문 류마티스 치료 접근성 확산으로 2024년 통풍 치료제 시장 매출의 50%를 차지했습니다.
통풍 치료에 대한 인식 증가, 의료 접근성 향상, 고요산혈증을 유발하는 생활습관병의 유병률 증가로 인해 아시아태평양 시장은 2025-2034년 가장 높은 CAGR을 나타낼 것으로 예측됩니다.
세계의 주요 기업에는 Arrowhead Pharmaceuticals, Inc., AstraZeneca, GSK plc., Eisai Co., Ltd., Merck & Co., Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Teijin Pharma Ltd., Zydus Group. 등이 있습니다.
목차
제1장 서론
제2장 개요
제3장 분석 방법
제4장 세계의 통풍 치료제 시장 인사이트
- 시장 스냅숏
- 통풍 치료제 시장 역학
- 촉진요인과 기회
- 통풍과 생활습관병의 유병률 상승
- 고령자 인구 기반의 확대
- 억제요인과 과제
- 신흥 시장에서 첨단 치료법의 고비용과 상환액의 한계
- 촉진요인과 기회
- PESTLE 분석
- 통풍 치료제 시장의 동향
- 밸류체인 분석
제5장 세계의 통풍 치료제 시장 : 약제 클래스별
- 주요 분석 결과
- 서론
- NSAID
- 코르티코스테로이드
- 콜히친
- 요산치 저하제
- 기타
제6장 세계의 통풍 치료제 시장 : 병상별
- 주요 분석 결과
- 서론
- 급성 통풍
- 만성 통풍
제7장 세계의 통풍 치료제 시장 : 유통 채널별
- 주요 분석 결과
- 서론
- 병원 약국
- 소매 약국
- 온라인 약국
제8장 세계의 통풍 치료제 시장 : 지역별
- 주요 분석 결과
- 서론
- 통풍 치료제 시장 분석 : 지역별(2020-2034년)
- 북미
- 북미 : 약제 클래스별(2020-2034년)
- 북미 : 병상별(2020-2034년)
- 북미 : 유통 채널별(2020-2034년)
- 미국
- 캐나다
- 유럽
- 유럽 : 약제 클래스별(2020-2034년)
- 유럽 : 병상별(2020-2034년)
- 유럽 : 유통 채널별(2020-2034년)
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 약제 클래스별(2020-2034년)
- 아시아태평양 : 병상별(2020-2034년)
- 아시아태평양 : 유통 채널별(2020-2034년)
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 약제 클래스별(2020-2034년)
- 중동 및 아프리카 : 병상별(2020-2034년)
- 중동 및 아프리카 : 유통 채널별(2020-2034년)
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 약제 클래스별(2020-2034년)
- 라틴아메리카 : 병상별(2020-2034년)
- 라틴아메리카 : 유통 채널별(2020-2034년)
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제9장 경쟁 구도
- 사업 확대·기업 인수 분석
- 사업 확대
- 기업 인수
- 제휴/협업/합의/공개
제10장 기업 개요
- Arrowhead Pharmaceuticals, Inc.
- AstraZeneca
- Eisai Co., Ltd.
- GSK plc.
- Merck & Co., Inc.
- Novartis AG
- Takeda Pharmaceutical Company Limited
- Teijin Pharma Ltd.
- Zydus Group
- Regeneron Pharmaceuticals Inc.
The gout therapeutics market size is expected to reach USD 6.15 billion by 2034, according to a new study by Polaris Market Research. The report "Gout Therapeutics Market Size, Share, Trend, Industry Analysis Report By Disease Condition (Acute Gout, Chronic Gout), By Drug Class, By Distribution Channel, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The gout therapeutics market addresses the clinical need for managing hyperuricemia and recurrent inflammatory arthritis resulting from monosodium urate crystal deposition. Treatment involves both acute management and long-term urate-lowering strategies to prevent flares and joint damage. Market growth is being driven by increasing disease burden, driven in part by rising obesity rates, sedentary lifestyles, and associated metabolic conditions such as hypertension and chronic kidney disease. Accelerated diagnostic timelines and increased awareness among both patients and healthcare providers are leading to earlier treatment initiation, expanding the patient pool for therapeutic intervention.
Industry players are investing in targeted therapies that minimize adverse events while offering improved efficacy, particularly for patients unresponsive to conventional treatment. Trends such as biologic innovation, precision medicine approaches, and focus on comorbidity-friendly formulations are gaining traction. Opportunities are emerging through pipeline expansion in urate transport modulation and interleukin-1B inhibition. Regulatory bodies are providing fast-track pathways for breakthrough therapies, encouraging R&D investments. Companies are forming strategic collaborations to co-develop and commercialize novel agents, leveraging shared expertise and regional market access. The market is also witnessing a shift toward patient-centric care models, incorporating treatment adherence tools and digital health integration.
Gout Therapeutics Market Report Highlights
By drug class, the NSAIDs segment dominated the market with ~43% of the revenue share in 2024 due to their rapid action in reducing inflammation and pain associated with acute gout flares.
Based on disease condition, the chronic gout segment held the largest revenue share in 2024 due to growing demand for long-term management therapies.
North America accounted for ~50% of the gout therapeutics market revenue share in 2024 due to strong healthcare infrastructure, early diagnosis, and widespread access to specialized rheumatology care.
The market in Asia Pacific is expected to register the highest CAGR from 2025 to 2034 due to growing awareness about gout treatment, improving healthcare access, and the rising prevalence of lifestyle diseases contributing to hyperuricemia.
A few global key players include Arrowhead Pharmaceuticals, Inc.; AstraZeneca; GSK plc.; Eisai Co., Ltd.; Merck & Co., Inc.; Novartis AG; Regeneron Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited; Teijin Pharma Ltd.; and Zydus Group.
Polaris Market Research has segmented the market report on the basis of disease condition, drug class, distribution channel, and region:
By Disease Condition Outlook (Revenue, USD Billion, 2020-2034)
Acute Gout
Chronic Gout
By Drug Class Outlook (Revenue, USD Billion, 2020-2034)
NSAIDs
Corticosteroids
Colchicine
Urate-Lowering Agents
Others
By Distribution Channel Outlook (Revenue, USD Billion, 2020-2034)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Regional Outlook (Revenue, USD Billion, 2020-2034)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Gout Therapeutics Market Insights
- 4.1. Gout Therapeutics Market - Market Snapshot
- 4.2. Gout Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising Prevalence of Gout and Lifestyle Disorders
- 4.2.1.2. Increased Geriatric Population Base
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High cost of advanced therapies and limited reimbursement in emerging markets.
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Gout Therapeutics Market Trends
- 4.6. Value Chain Analysis
5. Global Gout Therapeutics Market, by Drug Class
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 5.3. NSAIDs
- 5.3.1. Global Gout Therapeutics Market, by NSAIDs, by Region, 2020-2034 (USD Billion)
- 5.4. Corticosteroids
- 5.4.1. Global Gout Therapeutics Market, by Corticosteroids, by Region, 2020-2034 (USD Billion)
- 5.5. Colchicine
- 5.5.1. Global Gout Therapeutics Market, by Colchicine, by Region, 2020-2034 (USD Billion)
- 5.6. Urate-Lowering Agents
- 5.6.1. Global Gout Therapeutics Market, by Urate-Lowering Agents, by Region, 2020-2034 (USD Billion)
- 5.7. Others
- 5.7.1. Global Gout Therapeutics Market, by Others, by Region, 2020-2034 (USD Billion)
6. Global Gout Therapeutics Market, by Disease Condition
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 6.3. Acute Gout
- 6.3.1. Global Gout Therapeutics Market, by Acute Gout, by Region, 2020-2034 (USD Billion)
- 6.4. Chronic Gout
- 6.4.1. Global Gout Therapeutics Market, by Chronic Gout, by Region, 2020-2034 (USD Billion)
7. Global Gout Therapeutics Market, by Distribution Channel
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 7.3. Hospital Pharmacy
- 7.3.1. Global Gout Therapeutics Market, by Hospital Pharmacy, by Region, 2020-2034 (USD Billion)
- 7.4. Retail Pharmacy
- 7.4.1. Global Gout Therapeutics Market, by Retail Pharmacy, by Region, 2020-2034 (USD Billion)
- 7.5. Online Pharmacy
- 7.5.1. Global Gout Therapeutics Market, by Online Pharmacy, by Region, 2020-2034 (USD Billion)
8. Global Gout Therapeutics Market, by Geography
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Gout Therapeutics Market Assessment, By Geography, 2020-2034 (USD Billion)
- 8.3. Gout Therapeutics Market - North America
- 8.3.1. North America: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.3.2. North America: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.3.3. North America: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.3.4. Gout Therapeutics Market - U.S.
- 8.3.4.1. U.S.: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.3.4.2. U.S.: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.3.4.3. U.S.: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.3.5. Gout Therapeutics Market - Canada
- 8.3.5.1. Canada: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.3.5.2. Canada: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.3.5.3. Canada: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4. Gout Therapeutics Market - Europe
- 8.4.1. Europe: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.4.2. Europe: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.4.3. Europe: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.4. Gout Therapeutics Market - UK
- 8.4.4.1. UK: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.4.4.2. UK: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.4.4.3. UK: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.5. Gout Therapeutics Market - France
- 8.4.5.1. France: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.4.5.2. France: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.4.5.3. France: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.6. Gout Therapeutics Market - Germany
- 8.4.6.1. Germany: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.4.6.2. Germany: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.4.6.3. Germany: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.7. Gout Therapeutics Market - Italy
- 8.4.7.1. Italy: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.4.7.2. Italy: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.4.7.3. Italy: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.8. Gout Therapeutics Market - Spain
- 8.4.8.1. Spain: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.4.8.2. Spain: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.4.8.3. Spain: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.9. Gout Therapeutics Market - Netherlands
- 8.4.9.1. Netherlands: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.4.9.2. Netherlands: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.4.9.3. Netherlands: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.10. Gout Therapeutics Market - Russia
- 8.4.10.1. Russia: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.4.10.2. Russia: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.4.10.3. Russia: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.11. Gout Therapeutics Market - Rest of Europe
- 8.4.11.1. Rest of Europe: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.4.11.2. Rest of Europe: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.4.11.3. Rest of Europe: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5. Gout Therapeutics Market - Asia Pacific
- 8.5.1. Asia Pacific: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.5.2. Asia Pacific: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.5.3. Asia Pacific: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.4. Gout Therapeutics Market - China
- 8.5.4.1. China: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.5.4.2. China: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.5.4.3. China: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.5. Gout Therapeutics Market - India
- 8.5.5.1. India: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.5.5.2. India: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.5.5.3. India: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.6. Gout Therapeutics Market - Malaysia
- 8.5.6.1. Malaysia: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.5.6.2. Malaysia: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.5.6.3. Malaysia: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.7. Gout Therapeutics Market - Japan
- 8.5.7.1. Japan: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.5.7.2. Japan: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.5.7.3. Japan: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.8. Gout Therapeutics Market - Indonesia
- 8.5.8.1. Indonesia: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.5.8.2. Indonesia: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.5.8.3. Indonesia: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.9. Gout Therapeutics Market - South Korea
- 8.5.9.1. South Korea: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.5.9.2. South Korea: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.5.9.3. South Korea: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.10. Gout Therapeutics Market - Australia
- 8.5.10.1. Australia: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.5.10.2. Australia: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.5.10.3. Australia: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.11. Gout Therapeutics Market - Rest of Asia Pacific
- 8.5.11.1. Rest of Asia Pacific: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.5.11.2. Rest of Asia Pacific: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.5.11.3. Rest of Asia Pacific: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6. Gout Therapeutics Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.6.2. Middle East & Africa: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.6.3. Middle East & Africa: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.4. Gout Therapeutics Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.6.4.2. Saudi Arabia: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.6.4.3. Saudi Arabia: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.5. Gout Therapeutics Market - UAE
- 8.6.5.1. UAE: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.6.5.2. UAE: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.6.5.3. UAE: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.6. Gout Therapeutics Market - Israel
- 8.6.6.1. Israel: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.6.6.2. Israel: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.6.6.3. Israel: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.7. Gout Therapeutics Market - South Africa
- 8.6.7.1. South Africa: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.6.7.2. South Africa: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.6.7.3. South Africa: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.8. Gout Therapeutics Market - Rest of Middle East & Africa
- 8.6.8.1. Rest of Middle East & Africa: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.6.8.2. Rest of Middle East & Africa: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.6.8.3. Rest of Middle East & Africa: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7. Gout Therapeutics Market - Latin America
- 8.7.1. Latin America: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.7.2. Latin America: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.7.3. Latin America: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.4. Gout Therapeutics Market - Mexico
- 8.7.4.1. Mexico: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.7.4.2. Mexico: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.7.4.3. Mexico: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.5. Gout Therapeutics Market - Brazil
- 8.7.5.1. Brazil: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.7.5.2. Brazil: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.7.5.3. Brazil: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.6. Gout Therapeutics Market - Argentina
- 8.7.6.1. Argentina: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.7.6.2. Argentina: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.7.6.3. Argentina: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.7. Gout Therapeutics Market - Rest of Latin America
- 8.7.7.1. Rest of Latin America: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
- 8.7.7.2. Rest of Latin America: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
- 8.7.7.3. Rest of Latin America: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Arrowhead Pharmaceuticals, Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. AstraZeneca
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Eisai Co., Ltd.
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. GSK plc.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Merck & Co., Inc.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Novartis AG
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Takeda Pharmaceutical Company Limited
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Teijin Pharma Ltd.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Zydus Group
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Regeneron Pharmaceuticals Inc.
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
